Treatment-related change versus tumor recurrence in high-grade gliomas: A diagnostic conundrum - Use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI

American Journal of Roentgenology

Volumn 198, Issue 1, 2012, Pages 19-26

  Fatterpekar, Girish M ^a   Galheigo, Diogo ^a   Narayana, Ashwatha ^a   Johnson, Glyn ^a   Knopp, Edmond ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Perfusion; Pseudoprogression; Pseudoresponse; Radiation necrosis; Tumor recurrence

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CORTICOSTEROID; FERUMOXYTOL; GADOTERIDOL; IRINOTECAN; TEMOZOLOMIDE;

ASTROCYTOMA; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; DYNAMIC SUSCEPTIBILITY CONTRAST ENHANCED PERFUSION MAGNETIC RESONANCE IMAGING; EDEMA; GLIOBLASTOMA; GLIOMA; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; NEUROTOXICITY; OUTCOME ASSESSMENT; PATHOLOGY; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RADIATION NECROSIS; REVIEW; TUMOR GROWTH; TUMOR RECURRENCE;

BRAIN NEOPLASMS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NECROSIS; NEOPLASM RECURRENCE, LOCAL; RADIATION INJURIES;

EID: 84455182223     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7417     Document Type: Review

References (52)

1. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280 (Pubitemid 20195640)
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996 (Pubitemid 40349501)
3. Finn MA, Blumenthal DT, Salzman KL, Jensen RL. Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 2007; 67:246-250 (Pubitemid 46274888)
4. Chamberlain MC, Glantz MJ, Chalmers L, van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007; 82:81-83
5. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). (abstract) J Clin Otol 2008; 26(suppl 15):2010b
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186
7. Bullitt E, Reardon DA, Smith JK. A review of micro- and macrovascular analysis in the assessment of tumor-associated vasculature as visualized by MR. Neuroimage 2007; 37(suppl 1):S116-S119 (Pubitemid 47243807)
8. Fellah S, Girard N, Chinot O, et al. Early evaluation of treatment response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility-weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2011; 29:e308-e311
9. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002; 223:11-29 (Pubitemid 34258186)
10. Bruening R, Kwong KK, Vevea MJ, et al. Echoplanar MR determination of relative cerebral blood volume in human brains: T1 versus T2 weighting. AJNR 1996; 17:831-840 (Pubitemid 126499953)
11. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999; 211:791-798 (Pubitemid 29249482)
12. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR 2002; 178:711-716 (Pubitemid 34178155)
13. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR 2003; 24:1989-1998 (Pubitemid 37444849)
14. Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am 2009; 19:527-557
15. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade whereas uncorrected maps do not. AJNR 2006; 27:859-867 (Pubitemid 44897737)
16. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008; 249:601-613
17. Barajas RF Jr, Chang JS, Segal M, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009; 253:486-496
18. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003; 9:180-188 (Pubitemid 36944725)
19. González DG, Menten J, Bosch DA, et al. Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study. Radiother Oncol 1994; 32:98-105 (Pubitemid 24270730)
20. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9:453-461 (Pubitemid 351597795)
21. Burger PC, Boyko OB. The pathology of central nervous system radiation injury. In: Gutin PH, Leibel SA, Sheline GE, eds. Radiation injury to the nervous system. New York, NY: Raven, 1991:191-208
22. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000; 217:377-384
23. Mullins ME, Barest GD, Schaefer PW, et al. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR 2005; 26:1967-1972
24. Bisdas S, Naegele T, Ritz R, et al. Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging. Acad Radiol 2011; 18:575-583
25. de Wit MC, de Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004; 63:535-537 (Pubitemid 39031388)
26. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gaspareto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR [Epub 2011 Mar 31]
27. Tsien C, Galban CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high grade glioma. J Clin Oncol 2010; 28:2293-2299
28. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep 2009; 9:241-246
29. Kang HC, Kim CY, Han JH, et al. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. J Neurooncol 2011; 102:157-162
30. Chamberlain MC. Pseudoprogression in glioblastoma. (letter and reply) J Clin Oncol 2008; 26:4359-4360
31. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009; 92:317-335
32. Sugahara T, Korogi Y, Tomiguchi S, et al. Post-therapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR 2000; 21:901-909 (Pubitemid 30262837)
33. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR 2009; 30:552-558
34. Gasparetto EL, Pawlak MA, Patel SH, et al. Post-treatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 2009; 250:887-896
35. Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 2010; 256:575-584
36. 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010; 112:758-765
37. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011; 79:514-523
38. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003 (Pubitemid 40349502)
39. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26:2192-2197
40. Kong DS, Kim ST, Kim EH, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR 2011; 32:382-387
41. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs procarbazine inpatients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83:588-593 (Pubitemid 30636298)
42. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-4729 (Pubitemid 350086473)
43. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745
44. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171: a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95 (Pubitemid 46075199)
45. Narayana A, Gutin PH, Recht LR, Leibel SA. Primary and metastatic brain tumors in adults. In: Hoppe R, Phillips TL, Roach M III, eds. Leibel and Phillips textbook of radiation oncology, 3rd ed. Philadelphia, PA: Saunders, 2010
46. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66:1258-1260 (Pubitemid 43739717)
47. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas. efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70:779-787
48. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61:6624-6628 (Pubitemid 32896475)
49. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306-314
50. Desjardins A, Reardon DA, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008; 14:7068-7073
51. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009; 69:5296-5300
52. 2-dominant extravasation correction in DS-MRI. Part II. Predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab 2011; 31:2054-2064